Dizal's Innovative Drug Birelentinib Earns Fast Track Status for CLL/SLL Treatment Dizal's birelentinib has received Fast Track Designation from the FDA for treating relapsed/refractory CLL/SLL, showing promising efficacy in clinical trials.

Dizal's Innovative Drug Birelentinib Earns Fast Track Status for CLL/SLL Treatment #Shanghai #United_States #CLL/SLL #Dizal #Birelentinib